OOIR: Observatory of International Research

Papers

(The H4-Index of Journal for Immunotherapy of Cancer is 68. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Author response to comment on “Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer	327
Response to "NLRC5 germline variants and their potential role in eliciting an immune response in patients with cancer treated with immune checkpoint inhibitors" by Xiang-Yu Meng	181
Zelig Eshhar (1941–2025): a tribute for a life for immunotherapy	161
Clinical value of tumor mutational burden for neoadjuvant and adjuvant immune checkpoint inhibitor in early-stage non-small cell lung cancer	155
Checkpoint inhibitor-expressing lentiviral vaccine suppresses tumor growth in preclinical cancer models	152
Constructing a pancancer ubiquitination regulatory network to determine tumor characteristics, immunotherapy response, and prognosis	144
Correction: PP4 inhibition sensitizes ovarian cancer to NK cell-mediated cytotoxicity via STAT1 activation and inflammatory signaling	140
Correction: Treg-selective IL-2 starvation synergizes with CD40 activation to sustain durable responses in lymphoma models	131
Correction: Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer	127
Correction: influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors	126
Correction: Dexmedetomidine induces immunogenic cancer cell death and sensitizes tumors to PD-1 blockade	126
Commentary on oncolytic viruses: past, present, and future	125
Clinical trial landscape of CAR-based cell therapy for gastrointestinal malignancies	117
Novel circulating microRNA signature for early detection and prognostication of checkpoint inhibitor-related pneumonitis	114
Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells	108
Serotonin transporter SERT: a novel immune checkpoint for CD8 ⁺ T cell antitumor therapy	107
Inhibition of PNCK inflames tumor microenvironment and sensitizes head and neck squamous cell carcinoma to immune checkpoint inhibitors	106
Novel CAR T cell blend targeting PDPN and GD2 to overcome glioblastoma heterogeneity	105
Pancreatic cancer cell-intrinsic transglutaminase-2 promotes T cell suppression through microtubule-dependent secretion of immunosuppressive cytokines	102
Is immunotherapy safe and effective in patients with VEXAS syndrome?	101
Cbl-b inhibitor NX-1607 activates MAPK/ERK signaling pathway and enhances T-cell activation	99
TIPE2 deletion improves the therapeutic potential of adoptively transferred NK cells	98
Differential phagocytosis induces diverse macrophage activation states in malignant gliomas	97
Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma	97
Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047	97

Serum analytes as predictors of disease recurrence and the duration of invasive disease-free survival in patients with triple negative breast cancer enrolled in the OXEL trial treated with immunothera	96
Evaluation of immune checkpoint inhibitor efficacy for solid tumors with CD274 (PD-L1 gene) amplification identified by comprehensive genomic profiling: retrospective study based on a nationwid	92
Immunotherapy reverses glioma-driven dysfunction of immune system homeostasis	91
B7-H3 CAR-T cell therapy combined with irradiation is effective in targeting bulk and radiation-resistant chordoma cancer cells	89
Engineering macrophages for effective and safe targeting of CD47 cancer cells in the tumor microenvironment	89
Galectin-9-driven immune evasion constrains radiotherapy-induced systemic antitumor immunity	88
T-cell tolerant fraction as a predictor of immune-related adverse events	86
New insights into the role of IFN-α/β and TLR7/8/9 in cancer immunotherapy and systemic autoimmunity	86
Tumor-associated macrophage-specific CD155 contributes to M2-phenotype transition, immunosuppression, and tumor progression in colorectal cancer	86
Macrophage-inherited exosome excise tumor immunosuppression to expedite immune-activated ferroptosis	86
Visceral adiposity and systemic inflammation in the obesity paradox in patients with unresectable or metastatic melanoma undergoing immune checkpoint inhibitor therapy: a retrospective cohort study	85
Single-cell analysis reveals clonally expanded tumor-associated CD57 ⁺ CD8 T cells are enriched in the periphery of patients with metastatic urotheli	84
Oncolytic adenovirus serotype 35 mediated tumor growth suppression via efficient activation of antitumor immunity	83
HDL-cholesterol confers sensitivity of immunotherapy in nasopharyngeal carcinoma via remodeling tumor-associated macrophages towards the M1 phenotype	82
TCR sequencing in cancer immunology and immunotherapy: what, when, where, why, and how	82
GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma	82
Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression	81
Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors	80
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy	79
Intratumoral microbiota predicts the response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer	79
Localization and density of tertiary lymphoid structures associate with molecular subtype and clinical outcome in colorectal cancer liver metastases	78
Hybrid epithelial-mesenchymal status of lung cancer dictates metastatic success through differential interaction with NK cells	77
MAIT cells promote cancer progression and regulatory T cell accumulation in bladder tumor microenvironment	77
Lactylation-driven TNFR2 expression in regulatory T cells promotes the progression of malignant pleural effusion	76
Patient-reported outcomes in adoptive cell-therapy trials: mind the gap	76
Serum albumin: a pharmacokinetic marker for optimizing treatment outcome of immune checkpoint blockade	76
Novel PAP-targeted CAR-T therapy enhances antitumor efficacy through CoupledCAR approach	75
EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses	75
Immune-related adverse events occurring rapidly after a single dose of immune checkpoint blockade	75
Biomarkers for response to TIL therapy: a comprehensive review	73
SAMHD1 drives immunosuppression in non-small cell lung cancer by promoting macrophage infiltration and restricting oncolytic adenovirus replication	71
Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision	71
Selective activation of interleukin-2/interleukin-15 receptor signaling in tumor microenvironment using paired bispecific antibodies	71
Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors	70
Vaccination generates functional progenitor tumor-specific CD8 T cells and long-term tumor control	70
Correction: Non-superagonist CD28-based dual-signal T cell engager targeting KK-LC-1 enhances antitumor efficacy	70
Correction: Antitumor strategies targeting macrophages: the importance of considering the differences in differentiation/polarization processes between human and mouse macrophages	70
Accumulation of T-cell-suppressive PD-L1^high extracellular vesicles is associated with GvHD and might impact GvL efficacy	69
Human blood cell transcriptomics unveils dynamic systemic immune modulation along colorectal cancer progression	69
Phase 2 trial of pTVG-HP ± pTVG-AR DNA vaccines and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)	69
Mutation-guided chemotherapy-free strategy in first-line immunotherapy for low PD-L1-expressing non-squamous NSCLC	69
Predictors of patients with advanced pancreatic cancer undergoing conversion surgery via chemoimmunotherapy with a multifunctional Wilms’ tumor 1 (WT1) peptide cocktail-pulsed dendritic cell vaccine	68
Addendum 1: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0	68